BNT327 achieved disease control in 67% of heavily pretreated lung cancer patients, including those resistant to prior checkpoint inhibitor therapy.
https://news.gmj.ge/briefs/67-disease-control-rate-bispecific-antibody-shows-efficacy-in-checkpoint-inhibitor-resistant-patients/
BNT327 achieved disease control in 67% of heavily pretreated lung cancer patients, including those resistant to prior checkpoint inhibitor therapy.
